针对瘤学药品剂量优化的FDA-AACR策略:使用创新的试验设计和生物标志物的早期试验
Olanrewaju O Okusanya1, Gabriela I Patilea-Vrana2, Anthony Sireci3
1U.S. Food and Drug Administration, Silver Spring, Maryland.
概括
使用最大耐受剂量 (MTD) 的传统瘤药物剂量选择对于现代药物来说是无效的. 早期确定最佳的瘤药物剂量需要创新的试验设计和先进的建模技术.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
- 药物开发 药物开发
背景情况:
- 传统的瘤药物开发依赖于最大耐受剂量 (MTD) 进行剂量选择.
- 这种基于MTD的方法往往导致新瘤治疗药物的低于最佳剂量.
- 市场后的剂量优化是昂贵和低效的,这促使监管机构要求改变.
研究的目的:
- 审查用于更早,更有效的瘤药物剂量选择的创新技术.
- 突出现代药物开发中传统的MTD范式的局限性.
- 概述在注册试验之前选择剂量进行进一步评估的最佳实践.
主要方法:
- 讨论超越MTD的适合目的技术.
- 探索创新的试验元素,如生物标志物和适应性设计 (例如,补充,随机剂量扩展队列).
- 整合建模方法,如临床效用指数,用于定量决策.
主要成果:
- 目前对MTD的依赖对于优化现代瘤药物剂量是不可持续的.
- 创新的试验设计和建模可以促进更早,更明智的剂量选择.
- 现有的先进策略在传统的MTD方法的支持下未得到充分利用.
结论:
- 早期确定最佳的瘤药物剂量对于药物开发效率至关重要.
- 建议采用创新的试验元素和建模技术,以改善剂量选择.
- 需要进一步开发和应用这些先进的方法来完善瘤学药物剂量策略.
更多相关视频
相关概念视频
Dosage Regimens: Designs and Approaches
263
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
263
Dosage Regimen: Individualization
166
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
166
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Biopharmaceutical Factors Influencing Drug Product Design: Overview
233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
Dosage Regimen Designs: Nomograms and Tabulations
181
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
181
Dosage Regimens: Partial Pharmacokinetic Parameters
154
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
154


